Biogen (NASDAQ:BIIB) is set to release its earnings data before the market opens on Thursday, January 25th. Analysts expect Biogen to post earnings of $5.54 per share for the quarter.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Tuesday, October 24th. The biotechnology company reported $6.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $5.70 by $0.61. The firm had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Biogen had a return on equity of 38.51% and a net margin of 29.44%. The company’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.19 earnings per share. On average, analysts expect Biogen to post $22 EPS for the current fiscal year and $24 EPS for the next fiscal year.

Shares of Biogen (NASDAQ BIIB) opened at $344.87 on Thursday. The company has a market capitalization of $72,930.00, a P/E ratio of 21.14, a PEG ratio of 1.91 and a beta of 0.73. Biogen has a 1-year low of $244.28 and a 1-year high of $348.84. The company has a current ratio of 2.19, a quick ratio of 1.90 and a debt-to-equity ratio of 0.46.

In other news, CEO Michel Vounatsos purchased 780 shares of the company’s stock in a transaction dated Friday, December 29th. The shares were purchased at an average price of $320.55 per share, with a total value of $250,029.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Robert W. Pangia sold 5,832 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $329.65, for a total value of $1,922,518.80. Following the transaction, the director now directly owns 23,539 shares in the company, valued at approximately $7,759,631.35. The disclosure for this sale can be found here. Insiders acquired a total of 31,560 shares of company stock valued at $10,020,858 in the last 90 days. Corporate insiders own 0.25% of the company’s stock.

Several research firms have recently commented on BIIB. Canaccord Genuity set a $350.00 price objective on Biogen and gave the company a “hold” rating in a report on Tuesday. Oppenheimer set a $380.00 price objective on Biogen and gave the company a “buy” rating in a report on Monday. Citigroup restated an “outperform” rating and set a $380.00 price objective (up previously from $350.00) on shares of Biogen in a report on Tuesday. BidaskClub upgraded Biogen from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Finally, Mizuho set a $400.00 price objective on Biogen and gave the company a “buy” rating in a report on Friday, January 5th. Nine equities research analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $353.75.

TRADEMARK VIOLATION NOTICE: “Biogen (BIIB) Scheduled to Post Earnings on Thursday” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at

About Biogen

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Earnings History for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with's FREE daily email newsletter.